FM
fazen.markets
healthcare·esfritzh

Vivos Therapeutics Q3 2026: Revenue Jumps 24% QoQ to $6.4M

0h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

vivos-therapeuticsvvossleep-apneanasdaq-compliancemedical-device
Sponsoredby Fazen Capital

AiX — Free Expert Advisor

Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.

Myfxbook verified No subscription XAUUSD M15
Get Free EA

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.

Key Takeaways

  • 1Vivos cut its quarterly operating loss 18% and regained Nasdaq compliance, but $0.2 million in cash leaves little room for error.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported third quarter 2026 revenue of $6.4 million on 16 November 2026, a 24% increase from $5.2 million in the second quarter, while its quarterly operating loss narrowed 18% year over year to $3.9 million from $4.7 million. The company also said it regained compliance with Nasdaq's minimum stockholders' equity requirement after closing its SOD Sciences transaction on 16 October 2026.

Context — Why Vivos' Q3 2026 Results Matter Now

The quarter marks a shift in Vivos' revenue mix. Service revenue rose 1% year over year to $4.6 million, while product revenue fell to $1.8 million from $2.2 million as the company deliberately moved away from selling appliances to dentists in its Vivos Integrated Provider program.

That pivot explains why total revenue for the three months ended 30 September 2026 came in at $6.4 million versus $6.8 million a year earlier, even as the sequential gain against the second quarter was 24%. The company is trading appliance volume for recurring service dollars tied to sleep testing and treatment at its Nevada operations.

Over the first nine months of 2026, service revenue climbed 57% to $12.1 million from $7.7 million, which the company attributed mainly to sleep testing and the treatment services that follow. Total nine-month revenue reached $16.7 million against $13.6 million for the same stretch of 2025.

The cost side moved in the opposite direction on a quarterly basis but not on a nine-month basis. Third quarter operating expenses fell 17% to $7.2 million from $8.7 million, helped by a $1.4 million reduction in general and administrative costs. For the nine months, operating expenses rose to $24.7 million from $21.1 million, driven by the cost of standing up two Sleep and Airway Medicine Centers in Las Vegas and Henderson, Nevada.

Chief Executive Kirk Huntsman said the company had eliminated an estimated $5 million or more in annual operating costs, with further efficiencies underway. That figure is the company's own estimate, not an audited result.

Data — The Numbers Behind Vivos' Quarter

The balance sheet changed materially during the year. Cash and cash equivalents stood at $0.2 million on 30 September 2026, down from $2.0 million on 31 December 2025. Total stockholders' equity swung to $2.4 million from a deficit of $1.5 million, and total liabilities fell to $20.7 million from $26.7 million.

Vivos said it exchanged roughly $6.1 million of senior secured debt for equity during 2026. The current portion of debt on the balance sheet dropped to $1.5 million from $8.4 million at year-end 2025, while the employee retention credit liability of $2.9 million was reversed, producing about $2.9 million of other income in the quarter.

MetricQ3 2026Q3 2025
Total revenue$6.4M$6.8M
Gross profit$3.3M$3.9M
Gross margin52%58%
Operating loss$3.9M$4.7M
Net loss$2.0M$5.4M

Gross margin compressed to 52% from 58% because of the product revenue decline, though the nine-month figure improved to 56% from 55%. Net loss per share was $0.07 for the quarter against $0.49 a year earlier, with the weighted average share count rising to 26.5 million from 11.0 million.

Analysis — What Vivos' Results Signal for Sleep-Health Equities

Vivos sits in a small cluster of listed sleep-apnea names, and its results speak to a broader question about whether device makers can convert one-time hardware sales into recurring service revenue. The company's own numbers show the trade-off clearly: product revenue is shrinking, service revenue is growing, and gross margin is caught in between.

The 18% improvement in quarterly operating loss matters because it was achieved while the company was funding two new clinical centers. If the Las Vegas and Henderson sites reach the utilization the company expects, the fixed-cost base is already in place. If they do not, the nine-month operating expense increase of $3.6 million becomes a drag rather than an investment.

A reasonable counter-argument is that the quarterly revenue decline versus the prior year is the more important figure. A 24% sequential gain off a soft second quarter does not erase a 5% year-over-year drop in total revenue. The company's growth story currently rests on service revenue, which rose just 1% year over year in the quarter even as it rose 57% over nine months — a deceleration worth watching.

The cash position is the sharpest limitation. With $0.2 million of cash at quarter-end, the company's liquidity depends on the debt-for-equity exchange, the SOD Sciences transaction and any further financing. Vivos did not disclose the terms of the SOD Sciences transaction in the report.

Positioning in a micro-cap like VVOS tends to be event-driven. The stock's float expanded sharply over the year as share count rose, which historically pressures per-share metrics and can attract short interest around financing events. The company's own guidance points to revenue and margin contributions from new clinical initiatives beginning in the fourth quarter of 2026.

Outlook — What to Watch for Vivos

Vivos named several catalysts it expects to contribute to revenue and margins starting in the fourth quarter of 2026 and increasingly through 2027: EEG testing and treatment for insomnia and other non-OSA sleep disorders, distribution and set-up of PAP and CPAP treatments, remote patient monitoring of CPAP users, and renegotiation of payer contracts.

The company did not provide specific revenue or earnings guidance for the fourth quarter or full-year 2027. Investors will get more detail on the conference call the company scheduled for 16 November 2026 at 5:00 pm Eastern time, with a replay available until 30 November 2026.

Nasdaq's compliance notice on 20 October 2026 was granted subject to continued monitoring, which means the equity requirement remains a live condition rather than a resolved item. The company's Form 10-Q for the quarter was filed with the SEC, and the full document is available on the investor relations section of its website.

Frequently Asked Questions

What does Vivos Therapeutics' Nasdaq compliance mean for shareholders?

Nasdaq notified Vivos on 20 October 2026 that it had regained compliance with the minimum stockholders' equity requirement after the SOD Sciences transaction closed. The relief is subject to continued monitoring, so the company must stay above the threshold. Compliance removes the immediate threat of delisting, but it does not change the underlying cash position of $0.2 million reported at quarter-end.

Why did Vivos' gross margin fall to 52% in Q3 2026?

The company attributed the decline to lower product revenue and higher cost of sales. Product revenue fell to $1.8 million from $2.2 million as Vivos deliberately shifted away from appliance sales to dentists in its Vivos Integrated Provider program. Service revenue carries a different cost structure, and the mix shift pulled the blended margin down from 58% a year earlier.

What is the SOD Sciences transaction and how did it affect Vivos?

Vivos completed the SOD Sciences transaction on 16 October 2026, after the quarter closed. The company said the closing was what allowed it to regain Nasdaq's stockholders' equity compliance. Vivos did not disclose the financial terms of the transaction in the report, so the deal's contribution to revenue or its purchase price remains unknown to investors.

Bottom Line

Vivos cut its quarterly operating loss 18% and regained Nasdaq compliance, but $0.2 million in cash leaves little room for error.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

Sponsored — AiX

Trade XAUUSD on autopilot — free Expert Advisor

AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.

Get Free EA

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related